THC Is Just an Ingredient — How Schedule III Will Reshape Cannabis, Pharma & Hemp

When it boils down to it, THC is just an ingredient. (See what I did there?)

From a manufacturing standpoint, it's simply a molecule — one that should be produced in safe, clean, compliant environments, just like every other active pharmaceutical ingredient.

And who actually does that today?

Not many people can say they've operated in all three worlds: traditional cannabis, emerging hemp, and licensed DEA Schedule I pharmaceutical manufacturing — both in the U.S. and internationally. But Zach Edge has.

That perspective matters. Because as these industries inevitably converge (sooner rather than later), plenty of folks will cling to their legacy silos, clutch their pearls, and miss the boat.

But what if instead of cannabis operators retrofitting their facilities to meet pharma-grade requirements… they had to buy cannabinoids from GMP-licensed manufacturers?

The supply chain would be flipped overnight.

Pharma would dominate manufacturing.

Vertically integrated operators would need to rethink their entire model.

And the messy roadmap ahead is exactly why Zach's insight is so valuable.

To be clear — I'm not saying that will happen. But I am saying this:

What got you here won't get you there.

The next phase isn't just about operational efficiency.

Extraction teams call me because your process needs visibility. And honestly — if you're not taking advantage of our Benchmark Program, it's insane. We've structured it to be literally risk-free.

The reality is bigger: it's about rewriting strategy and hedging your bets.

In my opinion, Zach is one of the most underrated voices in the space. His vantage point across pharma, hemp, and cannabis gives him a clear view of the inevitable collision between these verticals — and why the playbook has to change.